| Literature DB >> 29666359 |
Na Zhu1, Xiao-Xiang Wu1,2, Yong Tian1, Jin-Xiu Zhu1,3, Jian-Chun Li1.
Abstract
BACKGROUND The aim of this study was to assess the pharmacokinetics after transdermal administration by a novel skin microdialysis technology in rats. The guinea pig model was established by investigating the pharmacodynamics. MATERIAL AND METHODS Three different agents were given after hair removal, and the samples were extracted by microdialysis and detected by HPLC. Subcutaneous/plasma concentration-time curves of the 3 different agents were analyzed and the pharmacokinetic parameters were calculated. The SS-04B UV light therapy instrument was used in the modeling. Changes in melanin index and histopathology were observed with HE staining. RESULTS The increment and decrement results showed that the concentration had no significant effect on drug recovery both in vivo and in vitro. After the paeonol cubic liquid crystalline nanoparticles gel (PAE-LCNPs) was administered, the maximum peak time (tmax) of paeonol skin concentration appeared at 2.42±0.20 h, the maximum skin concentration Cmax was (926±105) ng/ml, and the area under the curve AUC0-8 was (8056±954) ng/h/ml. The tmax was shortened much more than in the other groups, and the performance of PAE-LCNPs targeting was good. Pharmacodynamic results showed that PAE-LCNPs can reduce melanocytes and reduce the melanin index, proving its utility in the treatment of melanin deposition. CONCLUSIONS The skin microdialysis study indicated PAE-LCNPs have good transdermal permeability and efficacy. Pharmacological experiments based on the study found that the topical pigmentation model of guinea pigs showed a better therapeutic effect.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29666359 PMCID: PMC5926275 DOI: 10.12659/msm.906140
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Chromatogram. (A) PAE solution; (B) Blank skin microdialysis fluids of PAE-LCNPs; (C) Skin microdialysis fluids of PAE-LCNPs.
Results of precision test (n=6).
| Drug amount (μg/ml) | RSD(%) | |
|---|---|---|
| Intra-day | Inter-day | |
| 0.108 | 1.77 | 2.54 |
| 0.87 | 0.98 | 1.17 |
| 6.95 | 1.06 | 1.35 |
Stability test.
| Time (h) | 0 | 2 | 4 | 6 | 8 | 12 | 24 | Mean (%) | RSD (%) |
|---|---|---|---|---|---|---|---|---|---|
| Drug amount (μg/ml) | 1.486 | 1.485 | 1.484 | 1.485 | 1.483 | 1.485 | 1.484 | 1.485 | 0.976 |
Recovery rate in vitro (mean ±SD, n=3).
| Drug amount (μg/ml) | Increment method (%) | Decrement method (%) |
|---|---|---|
| 0.186 | 45.83±1.06 | 48.65±2.37 |
| 0.372 | 47.30±1.58 | 50.66±1.80 |
| 0.744 | 48.50±0.94 | 49.13±1.12 |
Recovery rate in vivo (mean ±SD, n=3).
| Drug amount μg/ml | Recovery rate % |
|---|---|
| 0.186 | 40.28±1.70 |
| 0.372 | 44.09±1.33 |
| 0.744 | 45.69±1.97 |
Figure 2Mean concentration-time profile of PAE. Each point represents the mean ±SD (n=3).
The pharmacokinetic parameters in different groups (mean ±SD, n=3).
| Parameter | Unit | PAE-LCNPs | PAE-OIT | PAE-GEL |
|---|---|---|---|---|
| ng/ml | 926±105 | 283±91 | 187±104 | |
| h | 2.42±0.20 | 3.04±0.33 | 4.22±0.54 | |
| AUC0–8 | ng/h/ml | 8056±954 | 3139±1023 | 1059±907 |
Compared with PAE-OIT:
P<0.05;
P<0.01;
Compared with PAE-GEL:
P<0.05;
P<0.01.
The retention of different groups after 8h (n=3).
| Samples | Cuticle (μg) | Epidermal/dermal (μg) |
|---|---|---|
| PAE-LCNPs | 67.15±3.50 | 31.09±3.29 |
| PAE-OIT | 36.65±2.12 | 17.97±1.58 |
| PAE-GEL | 50.56±3.37 | 24.08±2.07 |
Compared with PAE-OIT:
P<0.01;
Compared with PAE-GEL:
P<0.05.
The change of melanin index before and after molding (mean ±SD).
| Group | n | Melanin index |
|---|---|---|
| Before molding | 10 | 140.10±51.83 |
| After molding | 10 | 347.60±76.52 |
Compared with Before molding:
P<0.01.
The change of melanin index before and after administering (mean ±SD).
| Group | n | Before administration | After administration |
|---|---|---|---|
| Vaseline | 5 | 346.70±74.15 | 315.90±86.55 |
| PAE-OIT | 5 | 343.50±93.90 | 289.70±96.03 |
| 3% HDC | 5 | 351.20±87.41 | 192.10±67.58 |
| PAE-LCNPs | 5 | 349.10±68.03 | 187.90±63.41 |
Compared with the Vaseline:
P>0.05;
Compared with the 3% HDC:
P>0.05;
Compared with the Vaseline and PAE-OIT:
P<0.01;
Compared with the Vaseline and PAE-OIT:
P<0.01.
Figure 3Before and after modeling of guinea pigs skin histopathological images (HE×100). (A) Before modeling; (B) After the model was not the medication group; (C) Vaseline drug group; (D) PAE-OIT drug group; (E) 3% hydroquinone cream application group; (F): PAE-LCNPs medication group.